Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -2.08% 2.35 3,187,154 08:33:19
Bid Price Offer Price High Price Low Price Open Price
2.30 2.40 2.40 2.29 2.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.54 -0.93 -0.16 14
Last Trade Time Trade Type Trade Size Trade Price Currency
16:37:09 O 157,923 2.30 GBX

Nuformix (NFX) Latest News

More Nuformix News
Nuformix Investors    Nuformix Takeover Rumours

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
09/4/202120:09Nuformix plc7,521

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Nuformix trades in real-time

Nuformix (NFX) Top Chat Posts

Nuformix Daily Update: Nuformix Plc is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 2.40p.
Nuformix Plc has a 4 week average price of 2.20p and a 12 week average price of 1.90p.
The 1 year high share price is 6.70p while the 1 year low share price is currently 1.90p.
There are currently 591,609,368 shares in issue and the average daily traded volume is 9,409,687 shares. The market capitalisation of Nuformix Plc is £13,902,820.15.
soupdragon55: Quotient ran the previous pharmacokinetic trials on NXP001 for NFX. In essence, NFX don't make anything themselves, they do the academic and research lab work, then outsource to have the drugs made and tested.
hollywood6: I hope the rise is due to the innovate grant.If its regarding Oxillo, what is a significant upfront payment? Will it be disclosed? Are you expecting huge share price rises from this? What will it add to the market cap? How will that reflect in the share price?
spurs90: Nfx The rise on Friday imo could be attributed to one of 2 things 1– Innovate UK Grant for the further development of NXP002 which, if successful, would supplement investment and provide important non-dilutive funding for the lead asset 2 - Oxilio oncology option The terms of its option agreement signed in September 2020 with Oxilio cover a licence for the development and exploitation of NXP001 in oncology. Deal terms include an undisclosed up-front payment to NFX offering an exclusive option period of 6 months, within which a global licensing agreement can be agreed, expiring 24 March 2021 VALUATION We evaluate the lead programme and look at recent deals in the IPF space to illustrate the value of NFX and its lead asset as it advances its strategy and/or secures new deals over the next 12-18 months. We use a DCF approach to value the lead programme NXP002 assuming global development and as it approaches key inflection points. We accept that this is the key focus and with the most certainty at present, until there is greater clarity on the way forward for NXP001 and for NXP004. We take into account that the programme is still at an early stage, nevertheless that risk is reduced owing to the existing body of safety data on the underlying drug, and because of the abbreviated regulatory route applicable for repurposed co-crystal or new solid form therapies. For simplicity, we look at the value of the asset as if NFX were to market the product, rather than via a licensing deal, to illustrate its worth to potential licensees. Our valuation of NXP002 as a preclinical asset using a 13% WACC gives a risk adjusted valuation of NFX of £52.8m which is equivalent to 9 pence per share (based on 591.6m shares in issue post funding). This assumes that a Phase I ready package for the asset is in place which is being developed over the next 12-18 months NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in upfront and milestone payments, plus single digit royalties on sales, increasing in value in proportion to the stage of development of the underlying asset: from feasibility up to the full Phase I ready GLP package, assuming successful outcomes and based on recent precedent. We illustrate a range of deal metrics in IPF to support our assumptions. Industry precedent shows that once a robust patent position is built, even early stage IPF assets are attracting significant deals in the indication. While pipelines are filling out, the novel approach, acute need and the inhaled route of administration are key factors that can differentiate NXP002. NEWSFLOW Over the next 12-18 months there are a number of possible events on the horizon: – Initiation of the feasibility studies on NXP002 in Q2 2021 – OutcomedecisiononOxiliooptiononNXP001. – News on patent filing outcomes, strategic path and partnering for NXP004 in oncology. – Outcome of Innovate UK Grant Application for NXP002 in Q1 2021. – Potential completion (subject to funding) of Phase I ready package for NXP002 by H1 2022. – Partneringnewsacrossthepipeline. – Corporate: FY results 12 months ended 31 March 2021 – date estimated July/August
for fx sake: There is nothing to be happy about here. They still haven't delivered any shareholder value.All Anne has done is pull back the veil to finally reveal what we suspected all along, that things were alot worse than we were led to believe.Aside from the NSB default, we now learn that the Asian deal was never close to a successful close. On top of that we have somehow 'lost' the 51m Ebers work and the Vistagen work too!This just raises massive questions about how the old board have behaved over the past 12 months and what has really gone on in that boardroom. I thought it was odd that Blackwell announced his departure when he did. I think I know the reason why now.So, we are now left in a position where the only near term possibility for adding shareholder value is a deal with Oxilio. However, the LTH's have been thrown under the bus in favour of new money. The investors get the heavily discounted price so they will immediately be quids in if a deal is struck. They probably won't stick around for too long after that though. Who here wouldn't cash their chips if they got back in the black? Any value from Oxilio will therefore be heavily sold into and the share price will dwindle down again as there are no other near term prospects.It looks, at best, like a long haul. Trust destroyed.
escapetohome: A disappointing share price performance.
jas964: I read that as positive news but such is the market apathy/faith(lack of) in NFX that the share price still needs checked for a pulse.
soupdragon55: NFX have 3 salaries to pay, the non-execs are not salaried. It's all in the company docs if you care to read them.Ebers pay for the work NFX do for them, so that's no issue. Oxilio will pay an up front fee on outlicensing. Again it's all in the company returns.
escapetohome: The share price action here is disappointing. Another disappointing day. Directors will soon be getting a letter from me asking them their strategy for rectification.
soupdragon55: It means Ebers will raise cash, they can then pay for more patent work from NFX. After that they can pay for development of the product and pay NFX milestones as per the £51m contract, then royalties follow. Ebers sole business plan uses NFX to generate the IP.
frogyboyo: Happy Christmas to you all. Let's pray the share price is many times higher this time next year.However I predict there will be no NFX this time next year which SHOULD be a good thing for us!!
Nuformix share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210414 18:24:48